All In Biotech

Drug Trial Radar · NCT01617967

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis

Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

29

Actual

Start

May 2012

Primary completion

Oct 2013

Study completion Jan 2014

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jun 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).

Conditions

  • TTR-mediated Amyloidosis

Interventions

  • PatisiranDrug

    Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug DiscontinuationTime frame: Up to 56 days post first dose

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    Le Kremlin-Bicêtre, France

  • Clinical Trial Site

    Marseille, France

  • Clinical Trial Site

    Münster, Germany

  • Clinical Trial Site

    Lisbon, Portugal

  • Clinical Trial Site

    Porto, Portugal

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Palma de Mallorca, Spain

  • Clinical Trial Site

    Umeå, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.